PROM1 and chronic granulomatous disease: There is already evidence that targeting HSC subpopulations for gene therapy could be a promising strategy for the future as demonstrated by CD133-targeted gene transfer into HSCs from a patient with the X-linked form of chronic granulomatous disease that resulted in a higher long-term HSC repopulating rate compared to untargeted gene transfer [38].